Miragen’s deal with Servier has potential of $1 billion

BOULDER – Miragen Therapeutics Inc., a Boulder-based biopharmaceutical company developing treatments for cardiovascular and muscle diseases, signed a research, development and commercialization deal with a French pharmaceutical company that could be worth as much as $1 billion.

The agreement with Les Laboratoires Servier will give Miragen up to $45 million upfront in exchange for worldwide commercialization rights, excluding the U.S. and Japan.

Miragen could receive $352 million if it hits commercial and clinical milestones, and when clinical development support is factored in the value to Miragen is about $1 billion, according to the release.

“Our agreement with Servier not only provides validation of…